Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Second-dose VITT: rare but real

Sue Pavord, Michael Makris

Blood (2022) 139 (17): 2581–2583.

https://doi.org/10.1182/blood.2022016118

Published: 2022

Journal Articles

Natural history of PF4 antibodies in vaccine-induced immune thrombocytopenia and thrombosis

Brian Craven, William Lester, Sara Boyce, Will Thomas, Angela Kanny, Claire Davies, Sue Pavord, Joannes Hermans, Michael Makris, Emily Bart-Smith, Sarah Arnott, Beverley J. Hunt, Pavel Chudakou, Anthony Calvert, Deepak Singh, Marie Scully

Blood (2022) 139 (16): 2553–2560.

https://doi.org/10.1182/blood.2021014684

Published: 2022

Includes: Supplemental data

Journal Articles

How Effective Are the Immunosuppressive Therapies Rituximab and Mycophenolate Mofetil in Immune Thrombocytopenia? Real World Evidence from the UK ITP Registry

Vickie McDonald, Gerorge Loughlin, Andrew Laws, Duncan Stacey, Jeffrey Spears, Atiqa Miah, Haroon Miah, Quentin Hill, Nichola Cooper, Michael Makris, Charlotte Bradbury, Adrian C. Newland

Blood (2021) 138 (Supplement 1): 1016.

https://doi.org/10.1182/blood-2021-152650

Published: 2021

Journal Articles

Hemophilia gene therapy is effective and safe

Michael Makris

Blood (2018) 131 (9): 952–953.

https://doi.org/10.1182/blood-2018-01-824144

Published: 2018

Journal Articles

A Factor VIII Fusion with an Inactivated FIX Generates a Biologically Active Molecule with Delayed Clearance in a FVIII/VWF Knockout Mouse Model

Oladipo Jude Akinwale, MSc,BSc, Ian Wilkinson, PhD, Christine Hough, PhD, David Lillicrap, MD FRCPC, Michael Makris, MD, Richard Ross, MD FRCP

Blood (2017) 130 (Supplement 1): 2344.

https://doi.org/10.1182/blood.V130.Suppl_1.2344.2344

Published: 2017

Journal Articles

Prospective Evaluation of Bleeding Incidence in Fibrinogen Deficiency (PRO-RBDD Study)

Blood (2016) 128 (22): 207.

https://doi.org/10.1182/blood.V128.22.207.207

Published: 2016

Journal Articles

Hemophilia A treatment: disruptive technology ahead

Michael Makris

Blood (2016) 127 (13): 1623–1624.

https://doi.org/10.1182/blood-2016-01-691469

Published: 2016

Journal Articles

Enrichment of FLI1 and RUNX1 mutations in families with excessive bleeding and platelet dense granule secretion defects

Jacqueline Stockley, Neil V. Morgan, Danai Bem, Gillian C. Lowe, Marie Lordkipanidzé, Ban Dawood, Michael A. Simpson, Kirsty Macfarlane, Kevin Horner, Vincenzo C. Leo, Katherine Talks, Jayashree Motwani, Jonathan T. Wilde, Peter W. Collins, Michael Makris, Steve P. Watson, Martina E. Daly

Blood (2013) 122 (25): 4090–4093.

https://doi.org/10.1182/blood-2013-06-506873

Published: 2013

Includes: Supplemental data

Journal Articles

Longer FVIII: the 4th generation

Michael Makris

Blood (2012) 119 (13): 2972–2973.

https://doi.org/10.1182/blood-2012-01-403675

Published: 2012

Journal Articles

Pharmacokinetic Behavior of IB1001, An Investigational Recombinant Factor IX, in Patients with Hemophilia B: Repeat Pharmacokinetic Study and Subgroup Analysis

Uri Martinowitz, MD, Amy D. Shapiro, MD, Doris V. Quon, MD, PhD, Miguel Antonio Escobar, MD, Christine L Kempton, MD, MSc, Peter Collins, MD, Pratima Chowdary, MD, Michael Makris, MD, Pier Mannuccio Mannucci, MD, Massimo Morfini, MD, Leonard A. Valentino, MD, Edward D. Gomperts, MD, Martin Lee, PhD

Blood (2011) 118 (21): 2267.

https://doi.org/10.1182/blood.V118.21.2267.2267

Published: 2011

Journal Articles

Safety of Recombinant Human Factor IX, Nonacog Alfa, for Usual Use In Pediatric Patients: Results From a Prospective Registry of European Hemophilia B Patients.

Pablo Rendo, MD, Erik Berntorp, MD, PhD, David M. Keeling, MD, Michael Makris, MD, Cedric R. Hermans, MD., PhD., Ereline Pauline Mauser-Bunschosten, Roberto Musso, Annarita Tagliaferri, Carl Kollmer, James Baumann, Robert Charnigo

Blood (2010) 116 (21): 3664.

https://doi.org/10.1182/blood.V116.21.3664.3664

Published: 2010

Journal Articles

Is VIII worse than IX?

Michael Makris

Blood (2009) 114 (4): 750–751.

https://doi.org/10.1182/blood-2009-04-217075

Published: 2009

Journal Articles

Thrombophilia: grading the risk

Michael Makris

Blood (2009) 113 (21): 5038–5039.

https://doi.org/10.1182/blood-2009-02-203281

Published: 2009

Journal Articles

Identification and characterization of a novel P2Y 12 variant in a patient diagnosed with type 1 von Willebrand disease in the European MCMDM-1VWD study

Martina E. Daly, Ban B. Dawood, William A. Lester, Ian R. Peake, Francesco Rodeghiero, Anne C. Goodeve, Michael Makris, Jonathan T. Wilde, Andrew D. Mumford, Stephen P. Watson, Stuart J. Mundell

Blood (2009) 113 (17): 4110–4113.

https://doi.org/10.1182/blood-2008-11-190850

Published: 2009

Journal Articles

Thrombin Generation Is Normal in Most Patients with Cirrhosis despite a Prolonged INR.

Alexander Gatt, MD, MRCP, FRCPath, Anne Riddell, Vincenza Calvaruso, Michael Makris, MD, Edward Tuddenham, Andrew Burroughs

Blood (2008) 112 (11): 1826.

https://doi.org/10.1182/blood.V112.11.1826.1826

Published: 2008

Journal Articles

Prothrombin Complex Concentrate for Warfarin Reversal: A Single Dose Is Effective for All INRs >4.5.

Alexander Gatt, MD, MRCP, FRCPath, Anne Riddell, Joost J van Veen, Steve Kitchen, Edward Tuddenham, Michael Makris, MD

Blood (2008) 112 (11): 1985.

https://doi.org/10.1182/blood.V112.11.1985.1985

Published: 2008

Journal Articles

Progression to end-stage liver disease in patients with inherited bleeding disorders and hepatitis C: an international, multicenter cohort study

Dirk Posthouwer, Michael Makris, Thynn T. Yee, Kathelijn Fischer, Joost J. van Veen, Anja Griffioen, Karel J. van Erpecum, Eveline P. Mauser-Bunschoten

Blood (2007) 109 (9): 3667–3671.

https://doi.org/10.1182/blood-2006-08-038349

Published: 2007

Journal Articles

Platelet-Activating Anti-Platelet Factor 4/Polyanion Antibodies without Preceding Heparin Therapy: A Transient Autoimmune Disorder Resembling Heparin-Induced Thrombocytopenia (“Spontaneous HIT”).

Theodore E. Warkentin, MD, Richard M. Jay, MD, Michael Makris, MD, John G. Kelton, MD

Blood (2006) 108 (11): 1047.

https://doi.org/10.1182/blood.V108.11.1047.1047

Published: 2006

Journal Articles

Reversal of Anticoagulation as Assessed by Thrombin Generation Measurement.

Alex Gatt, MD, Joost van Veen, MD, Peter Cooper, Steve Kitchen, PhD, Michael Makris, MD

Blood (2006) 108 (11): 876.

https://doi.org/10.1182/blood.V108.11.876.876

Published: 2006

Journal Articles

A Novel Protac®-Modified Thrombin Generation Assay To Identify Individuals at Higher Thrombotic Risk.

Alex Gatt, MD, Joost van Veen, MD, Peter Cooper, Steve Kitchen, PhD, Michael Makris, MD

Blood (2006) 108 (11): 1472.

https://doi.org/10.1182/blood.V108.11.1472.1472

Published: 2006

NARROW

Second-dose VITT: rare but real

Natural history of PF4 antibodies in vaccine-induced immune thrombocytopenia and thrombosis

How Effective Are the Immunosuppressive Therapies Rituximab and Mycophenolate Mofetil in Immune Thrombocytopenia? Real World Evidence from the UK ITP Registry

Hemophilia gene therapy is effective and safe

A Factor VIII Fusion with an Inactivated FIX Generates a Biologically Active Molecule with Delayed Clearance in a FVIII/VWF Knockout Mouse Model

Prospective Evaluation of Bleeding Incidence in Fibrinogen Deficiency (PRO-RBDD Study)

Hemophilia A treatment: disruptive technology ahead

Enrichment of FLI1 and RUNX1 mutations in families with excessive bleeding and platelet dense granule secretion defects

Longer FVIII: the 4th generation

Pharmacokinetic Behavior of IB1001, An Investigational Recombinant Factor IX, in Patients with Hemophilia B: Repeat Pharmacokinetic Study and Subgroup Analysis

Safety of Recombinant Human Factor IX, Nonacog Alfa, for Usual Use In Pediatric Patients: Results From a Prospective Registry of European Hemophilia B Patients.

Is VIII worse than IX?

Thrombophilia: grading the risk

Identification and characterization of a novel P2Y 12 variant in a patient diagnosed with type 1 von Willebrand disease in the European MCMDM-1VWD study

Thrombin Generation Is Normal in Most Patients with Cirrhosis despite a Prolonged INR.

Prothrombin Complex Concentrate for Warfarin Reversal: A Single Dose Is Effective for All INRs >4.5.

Progression to end-stage liver disease in patients with inherited bleeding disorders and hepatitis C: an international, multicenter cohort study

Platelet-Activating Anti-Platelet Factor 4/Polyanion Antibodies without Preceding Heparin Therapy: A Transient Autoimmune Disorder Resembling Heparin-Induced Thrombocytopenia (“Spontaneous HIT”).

Reversal of Anticoagulation as Assessed by Thrombin Generation Measurement.

A Novel Protac®-Modified Thrombin Generation Assay To Identify Individuals at Higher Thrombotic Risk.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only